Funded Startups in Petah Tiqva
Nineteen funded startups list rounds from 2020-09-09 (Pcysys) through 2026-04-21 (Bioxtreme).
Nineteen funded startups list rounds from 2020-09-09 (Pcysys) through 2026-04-21 (Bioxtreme). In the disclosed-amount subset, the largest round is CanFite BioPharma’s $4M on 2026-03-04, and it sits in the same overall range as other disclosed figures rather than dwarfing them; at the low end, SolidT’s $50K on 2023-05-23 is the smallest disclosed amount. The round dates cluster tightly in the most recent window: five entries land between 2024-05-27 (Unlimited Robotics) and 2024-11-07 (Airobotics), while the latest month of 2026 contains two rows (Bioxtreme on 2026-04-21 is undisclosed; CanFite is $4M on 2026-03-04). Sector mix is also skewed toward biotechnology (CanFite BioPharma, PolyPid, DreaMed Diabetes, and Digma Medical), and a large share of entries provide no disclosed amount or no stage detail: three are “undisclosed” on amounts (Bioxtreme, NitroFix, Deep Optics, plus Digma Medical and others), and five carry “Series Unknown” or blank stage classifications (e.g., Bioxtreme, NitroFix, Airobotics, DreaMed Diabetes, Deep Optics).
Most recent rounds
19 shownRelated listings
Frequently asked
What’s the largest disclosed round shown for Petah Tiqva, and how far above the rest are the disclosed rounds?
CanFite BioPharma’s $4M (2026-03-04) is the largest disclosed amount in the table; the next disclosed figures are not in a much higher band, ranging from Airobotics’ $1M (2024-11-07) to Ingonyama’s $20M (2023-11-09) being the clearest higher disclosed step. SolidT’s $50K (2023-05-23) is the smallest disclosed amount.
Do these rounds cluster in time, especially around 2024–2025?
Yes. Five entries close between 2024-05-27 (Unlimited Robotics, $5M) and 2024-11-07 (Airobotics, $1M), and additional activity appears in 2025 with Pentera’s $60M on 2025-03-12 and NitroFix’s undisclosed round on 2025-01-01.
Which stage labels dominate, and are “Series Unknown” and blank stages common?
Stage information is frequently non-specific: five rows are explicitly “Series Unknown” (Bioxtreme, NitroFix, Airobotics, DreaMed Diabetes, PolyPid) and several additional rows have a blank stage field (Noveto Systems, Twine Solutions, Pcysys). Named stages that do appear include Seed (Unlimited Robotics on 2024-05-27; Ingonyama on 2023-11-09) and Series B/C/D (NsKnox on 2023-01-18, Deep Optics on 2022-11-08, Pentera on 2025-03-12).
Is any sector over-represented compared with others in this Petah Tiqva list?
Biotechnology appears repeatedly: CanFite BioPharma (2026-03-04, $4M), PolyPid (2024-08-01, $8M), and Digma Medical (2022-06-07, undisclosed) are all listed as Biotechnology. DreaMed Diabetes is categorized as AI on 2024-08-19 ($3M), which still sits close to the same 2024 biotech-adjacent window.
Which entries look like outliers on disclosed amounts or under-disclosed rounds?
Pentera’s $60M (2025-03-12, Series D) is a standout high disclosed round relative to many other disclosed amounts like SolidT’s $50K (2023-05-23) and Airobotics’ $1M (2024-11-07). On the other side, several recent rounds are undisclosed in amount—Bioxtreme on 2026-04-21, NitroFix on 2025-01-01, and Deep Optics on 2022-11-08—making comparisons across sectors harder for those entries.
What portion of the list falls within the most recent 90 days of the latest row date?
The latest row is dated 2026-04-21 (Bioxtreme, undisclosed). Within roughly the prior 90 days, two rows appear: Bioxtreme (2026-04-21) and CanFite BioPharma (2026-03-04, $4M).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.